Drug intelligence / Profile preview

AB-106 + itraconazole

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral

Overview

AB-106 + itraconazole is a **combination therapy** consisting of taletrectinib (AB-106) and itraconazole. AB-106 (taletrectinib) is an orally available small molecule **kinase inhibitor** targeting receptor tyrosine kinases ROS1 and neurotrophic tyrosine receptor kinases (NTRK) 1, 2, and 3. It disrupts ROS1- and NTRK-mediated signaling, thereby arresting tumor growth in cancers overexpressing these kinases. Itraconazole is an azole-type antifungal that inhibits ergosterol biosynthesis by blocking fungal cytochrome P450 14α-demethylase, leading to defective cell membrane integrity. This combination may enhance antineoplastic activity or be investigated for synergistic effects in oncology or fungal infection settings.

Brand names: Ibtrozi
Other names: taletrectinibDS-6051DS6051DS 6051DS-6051aDS6051aDS 6051a

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)NTRK3 (Tropomyosin receptor kinase C)NTRK1 (Tropomyosin-related receptor kinase A)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)CYP3A7 (Cytochrome P450 3A7)

Beyond the preview

Go deeper on AB-106 + itraconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-106 + itraconazole.

Explore the full profile